VERAPAMIL HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Verapamil Hydrochloride patents expire, and what generic alternatives are available?
Verapamil Hydrochloride is a drug marketed by Mylan, Rising, Abraxis Pharm, Acic Pharms, Bedford, Eugia Pharma, Gland Pharma Ltd, Hospira, Intl Medication, Luitpold, Mankind Pharma, Marsam Pharms Llc, Smith And Nephew, Solopak, Zydus Pharms, Amneal, Areva Pharms, Caplin, Exela Pharma, Micro Labs, Somerset, Somerset Theraps Llc, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Pliva, Strides Pharma, Sun Pharm Inds Inc, Actavis Elizabeth, Chartwell Rx, Heritage Pharms, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, and Watson Labs. and is included in sixty-four NDAs.
The generic ingredient in VERAPAMIL HYDROCHLORIDE is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Verapamil Hydrochloride
A generic version of VERAPAMIL HYDROCHLORIDE was approved as verapamil hydrochloride by EXELA PHARMA on March 30th, 1984.
Summary for VERAPAMIL HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 36 |
NDAs: | 64 |
Finished Product Suppliers / Packagers: | 42 |
Raw Ingredient (Bulk) Api Vendors: | 150 |
Clinical Trials: | 148 |
Patent Applications: | 2,869 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in VERAPAMIL HYDROCHLORIDE? | VERAPAMIL HYDROCHLORIDE excipients list |
DailyMed Link: | VERAPAMIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for VERAPAMIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Benha University | N/A |
Canisius-Wilhelmina Hospital | Phase 2 |
Leiden University Medical Center | Phase 2 |
Pharmacology for VERAPAMIL HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for VERAPAMIL HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for VERAPAMIL HYDROCHLORIDE
Paragraph IV (Patent) Challenges for VERAPAMIL HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VERELAN PM | Extended-release Capsules | verapamil hydrochloride | 100 mg and 200 mg | 020943 | 1 | 2006-07-20 |
VERELAN PM | Extended-release Capsules | verapamil hydrochloride | 300 mg | 020943 | 1 | 2006-05-19 |
US Patents and Regulatory Information for VERAPAMIL HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mutual Pharm | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | TABLET;ORAL | 070482-001 | Sep 24, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Somerset Theraps Llc | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 211015-001 | Jun 18, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Exela Pharma | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | SOLUTION;INTRAVENOUS | 018925-002 | Apr 5, 2018 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Watson Labs | VERAPAMIL HYDROCHLORIDE | verapamil hydrochloride | TABLET;ORAL | 070855-001 | Sep 24, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |